Cytek Biosciences (CTKB) Capital Expenditures Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -6.72% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 15.89% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -47.73% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -11.95% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -43.42% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 27.22% |
| 10 | Cytek Biosciences | - | - | 21.25 Mn | 54.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.06% |
| Dec 31, 2025 | -43.59% |
| Sep 30, 2025 | -53.91% |
| Jun 30, 2025 | 18.39% |
| Mar 31, 2025 | 194.79% |
| Dec 31, 2024 | -98.29% |
| Sep 30, 2024 | -2,404.55% |
| Jun 30, 2024 | 380.42% |
| Mar 31, 2024 | -42.97% |
| Dec 31, 2023 | 236.69% |
| Sep 30, 2023 | 512.50% |
| Jun 30, 2023 | 10.21% |
| Mar 31, 2023 | -35.26% |
| Dec 31, 2022 | 872.57% |
| Sep 30, 2022 | 44.83% |
| Jun 30, 2022 | -209.36% |
| Mar 31, 2022 | 53.24% |
| Dec 31, 2021 | 86.98% |
| Sep 30, 2021 | -106.12% |